{
    "organizations": [],
    "uuid": "60445fd65b4f0835964b9844ca3584a65eb809c5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-guangdong-zhongsheng-pharmaceutica/brief-guangdong-zhongsheng-pharmaceutical-receives-patent-certificate-from-israel-patent-office-idUSL3N1RO2ZA",
    "ord_in_thread": 0,
    "title": "BRIEF-Guangdong Zhongsheng Pharmaceutical receives patent certificate from Israel patent office",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 11 (Reuters) - Guangdong Zhongsheng Pharmaceutical Co Ltd\n* Says it received patent certificate(NO. 247970) named QUINOLINE DERIVATIVES AS SMO INHIBITORS, from Israel patent office\n* Patent valid for 20 years since March 16, 2015\nSource text in Chinese: goo.gl/33KJwH\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-04-11T14:37:00.000+03:00",
    "crawled": "2018-04-12T13:56:01.054+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "guangdong",
        "zhongsheng",
        "pharmaceutical",
        "co",
        "ltd",
        "say",
        "received",
        "patent",
        "certificate",
        "named",
        "quinoline",
        "derivative",
        "smo",
        "inhibitor",
        "israel",
        "patent",
        "office",
        "patent",
        "valid",
        "year",
        "since",
        "march",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}